10/13/2026
🔎 Ibogaine Research Is Advancing—But Approval Has Not Arrived
Ibogaine is moving into a more formal federal research conversation.
FDA is asking for public input on how early-phase ibogaine trials should be designed—including who should participate, how doses should be selected and what safeguards are needed to monitor potentially serious cardiac and neurological effects.
Researchers are exploring possible uses involving opioid-use disorder, PTSD and alcohol-use disorder. But an important distinction can easily get lost:
Being studied does not mean proven.
Promising does not mean safe.
And research authorization does not mean FDA approval.
As public interest grows, prevention professionals can help communities understand the difference between carefully monitored clinical research, unapproved treatment claims and unsupervised use. We can support legitimate research while still asking hard questions about safety, informed consent, marketing and how emerging information is communicated to people urgently seeking help.
FDA is accepting public comments through November 20, 2026.
Learn more: https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research
What questions do you believe must be answered before access to ibogaine expands?